Which anesthetic is commonly associated with a risk of thrombosis when used in high doses?

Etomidate is commonly associated with a risk of thrombosis when used in high doses due to its potential effects on the coagulation system. This anesthetic is known for its minimal cardiovascular effects, which makes it a popular choice in certain clinical settings, particularly in emergency and critical care. However, when administered in high doses, it can lead to complications such as thromboembolic events.

The mechanism behind this increased risk is not entirely understood, but it has been suggested that etomidate may influence platelet function or the coagulation cascade in a way that predisposes patients to thrombosis. Therefore, careful consideration and monitoring are recommended when using etomidate, particularly in patients who may already have an elevated risk for thromboembolic complications.

Other anesthetic agents such as ketamine, propofol, and midazolam have different profiles and mechanisms of action that do not typically include a significant association with thrombosis, even at higher doses. Ketamine, for example, is often used for its analgesic and dissociative properties and does not display the same risk profile, while propofol's effects center around its rapid onset and short duration of action for sedation. Midazolam is primarily a sedative with anxiolytic effects and